Amphastar Pharmaceuticals Inc (AMPH) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket
 


Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)

Amphastar Pharmaceuticals Inc Profitability Comparisons

Select each Category to receive further Information




AMPH Profitability Ratio

Company Industry Sector S&P 500
Gross Profit Margin (Q1 MRQ) 41.08 % 70.91 % 65.43 % 46.08 %
Gross Margin (Q1 TTM) 47.34 % 71.7 % 65.99 % 46.3 %
Gross Profit Margin 5 Yr. Avg. 50.1 % 67.81 % 65.55 % 48.95 %
EBITDA Margin (Q1 MRQ) 14.7 % 21.45 % 18.99 % 20.49 %
EBITDA Margin (Q1 TTM) 22.71 % 25.15 % 21.01 % 20.13 %
EBITDA Margin 5 Yr. Avg. 30.57 % 47.09 % 31.38 % 23.41 %
Operating Margin (Q1 MRQ) 7.96 % 17.27 % 16.58 % 16.05 %
Operating Margin (Q1 TTM) 16.2 % 20.33 % 17.81 % 16.34 %
Operating Margin 5 Yr. Avg. 23.13 % 15.37 % 14.33 % 19.26 %
Pre-Tax Profit Margin (Q1 MRQ) 5.87 % 13.66 % 10.94 % 13.96 %
Pre-Tax Profit Margin (Q1 TTM) 14.27 % 16.7 % 12.79 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. 22.43 % 12.98 % 10.37 % 13.52 %
Net Margin (Q1 MRQ) 3.75 % 10.09 % 8.15 % 11.42 %
Net Margin (Q1 TTM) 11 % 13.13 % 9.94 % 10.76 %
Net Margin 5 Yr. Avg. 17.91 % 5.79 % 6.08 % 10.8 %



Business Segment Profit Margin
 
Research and development services ANP
  Explore Research and development services ANP Segment  -
Accounts Receivable
  Explore Accounts Receivable Segment  -
Accounts Payable and Accrued Liabilities
  Explore Accounts Payable and Accrued Liabilities Segment  -
UNITED STATES
  Explore UNITED STATES Segment  -
Pharmaceutical products segment
  Explore Pharmaceutical products segment Segment  3.75 %
Finished Pharmaceutical Products Segment
  Explore Finished Pharmaceutical Products Segment Segment  -
Finished Pharmaceutical Products Glucagon
  Explore Finished Pharmaceutical Products Glucagon Segment  -
Finished Pharmaceutical Products Primatene MIST
  Explore Finished Pharmaceutical Products Primatene MIST Segment  -
Finished Pharmaceutical Products BAQSIMI
  Explore Finished Pharmaceutical Products BAQSIMI Segment  -
Finished Pharmaceutical Products Epinephrine
  Explore Finished Pharmaceutical Products Epinephrine Segment  -
Finished Pharmaceutical Products Lidocaine
  Explore Finished Pharmaceutical Products Lidocaine Segment  -
Finished Pharmaceutical Products Other Products
  Explore Finished Pharmaceutical Products Other Products Segment  -
China
  Explore China Segment  -
France
  Explore France Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q1 MRQ) 22.39 % -0.01 % 0.21 % 1.39 %
Free Cash Flow Margin (Q1 TTM) 18.45 % 17.24 % 13.85 % 9.11 %
Free Cash Flow Margin 5 Yr. Avg. - 19.28 % 14.86 % 15.58 %
Net Cash Flow Margin (Q1 MRQ) 0.45 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q1 TTM) -1.64 % -0.66 % 0.13 % 1.85 %
Net Cash Flow Margin 5 Yr. Avg. - 4.38 % 3.16 % 6.44 %
Effective Tax Rate (Q1 MRQ) 36.13 % 25.98 % 25.39 % 18.83 %
Effective Tax Rate (Q1 TTM) 22.94 % 21.21 % 22.93 % 19.44 %
Effective Tax Rate 5 Yr. Avg. 19.92 % 15.08 % 20.51 % 19.76 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.